Patent Litigation Seminar
Wednesday, March 18, 2015
Hotel Woodbridge at Metropark
120 Wood Avenue South, Iselin, NJ
(732) 494-6200
CLE: 4.0 PA, 4.5 NJ/NY (pending confirmation)
Event Fee: $125 Corporate/Government Employee
$100 Corporate/Government Employee - NJIPLA Member
$225 General Registration
$180 General Registration - NJIPLA Member
Program:
Noon – 12:45 p.m. Luncheon
12:45 – 12:50 p.m. Introduction
Jon A. Chiodo - President, NJIPLA
Johnson & Johnson (New Brunswick, NJ)
12:50 – 1:00 p.m. Opening Remarks by the Chair
Immac J. Thampoe
Merck & Co., Inc. (Rahway, NJ)
1:00 – 1:45 p.m. Will Congress and the Supreme Court End America's Lead in Health Science Technology and Sap the Strength of Our Industries?
Hon. Paul R. Michel
Chief Judge (Ret.) - United States Court of Appeals for the Federal Circuit
1:45 – 2:30 p.m. The New Standard of Review: The Supreme Court’s Decision in Teva v. Sandoz and the Return of the Fact/Law Distinction in Claim Construction
William M. Jay
Goodwin Procter, LLP (Washington, DC)
2:30– 3:15 p.m. Alice Arrived and Look What Happened: A Review of the Supreme Court’s June 2014 Decision and its Impact on Patents
Brian M. Buroker
Gibson Dunn & Crutcher LLP (Washington, DC)
3:15– 3:45 p.m. BREAK
3:45 – 4:30 p.m. The Rule Against Double Patenting in the Post-Gilead Era -- How We Got Here and What Will Happen Next
Jeremy Lowe
Axinn, Veltrop & Harkrider LLP (Hartford, CT)
4:30 – 5:30 p.m. Biosimilars Litigation: What’s Happening on the Dance Floor?
Lisa M. Pensabene
O’Melveny & Myers LLP (New York, NY)